Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.berh.2021.101659 http://scihub22266oqcxt.onion/10.1016/j.berh.2021.101659 33526326!7833968!33526326     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Best+Pract+Res+Clin+Rheumatol 2021 ; 35 (1): 101659 Nephropedia Template TP {{tp|p=33526326|t=2021. The protective effect of rheumatic disease agents in COVID-19 |pdf=|usr=}}{{33526326}} gab.com Text The protective effect of rheumatic disease agents in COVID-19 JO: Best Pract Res Clin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=33526326 #FOAvip Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-alpha) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants. Twit Text FOAVip The protective effect of rheumatic disease agents in COVID-19 ????Best Pract Res Clin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=33526326 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33526326 #FOAvip English Wikipedia <ref>{{Cite pmid|33526326}}</ref> The protective effect of rheumatic disease agents in COVID-19 #MMPMID33526326 Valenzuela-Almada MO; Putman MS; Duarte-Garcia A Best Pract Res Clin Rheumatol 2021[Mar]; 35 (1): 101659 PMID33526326show ga Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-alpha) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants. |*Antirheumatic Agents/therapeutic use[MESH] |*COVID-19[MESH] |*Rheumatic Diseases/drug therapy[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH]The protective effect of rheumatic disease agents in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing